Entrada Therapeutics (TRDA) Operating Income (2022 - 2025)
Historic Operating Income for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$47.1 million.
- Entrada Therapeutics' Operating Income fell 11724.54% to -$47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.6 million, marking a year-over-year decrease of 31036.81%. This contributed to the annual value of $47.0 million for FY2024, which is 158674.89% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Operating Income is -$47.1 million, which was down 11724.54% from -$46.8 million recorded in Q2 2025.
- Entrada Therapeutics' Operating Income's 5-year high stood at $53.4 million during Q2 2024, with a 5-year trough of -$47.1 million in Q3 2025.
- In the last 4 years, Entrada Therapeutics' Operating Income had a median value of -$21.7 million in 2024 and averaged -$11.3 million.
- Within the past 5 years, the most significant YoY rise in Entrada Therapeutics' Operating Income was 46527.68% (2024), while the steepest drop was 25456.75% (2024).
- Over the past 4 years, Entrada Therapeutics' Operating Income (Quarter) stood at -$25.6 million in 2022, then skyrocketed by 119.18% to $4.9 million in 2023, then tumbled by 219.61% to -$5.9 million in 2024, then crashed by 701.96% to -$47.1 million in 2025.
- Its last three reported values are -$47.1 million in Q3 2025, -$46.8 million for Q2 2025, and -$21.8 million during Q1 2025.